85 results
10-K/A
2023 FY
PHAT
Phathom Pharmaceuticals Inc
14 Jun 24
Annual report (amended)
4:05pm
December 31, | ||||||||
2023 | 2022 | |||||||
Accrued research and development expenses | $ | 1,009 | $ | 3,080 | ||||
Accrued compensation expenses | 13,318 | 8,447 | ||||||
Accrued professional & consulting expenses | 1,771 | 3,000 | ||||||
Accrued sales discounts and allowances | 982 | — | ||||||
Accrued other | 117 | 151 | ||||||
Total accrued expenses | $ | 17,197 | $ | 14,678 |
10-K/A
2023 FY
PHAT
Phathom Pharmaceuticals Inc
14 Jun 24
Annual report (amended)
4:05pm
Incorporated by Reference | |||||||||||
Exhibit Number | Exhibit Description | Form | Date | Number | Filed Herewith | ||||||
3.1 | Amended and Restated Certificate of Incorporation | 8-K | 10-29-2019 | 3.1 | |||||||
3.2 | Certificate of Amendment to Amended and Restated Certificate of Incorporation, as filed with the Secretary of the State of Delaware on May 26, 2023 | 8-K | 5-30-2023 | 3.1 | |||||||
3.3 | Amended and Restated Bylaws, effective as of December 13, 2023 | 8-K | 12-15-2023 | 3.1 | |||||||
4.1 | Form of Common Stock Certificate | S-1/A | 10-15-2019 | 4.1 | |||||||
4.2 | Warrant to purchase stock issued to Silicon Valley Bank, dated May 14, 2019 | S-1 | 9-30-2019 | 4.3 | |||||||
4.3 | Warrant to purchase stock issued to WestRiver Innovation Lending Fund VIII, L.P., dated May 14, 2019 | S-1 | 9-30-2019 | 4.4 | |||||||
4.4 | Note Purchase Agreement, dated May 7, 2019, by and among the Registrant and the other parties party thereto, as amended | S-1/A | 10-15-2019 | 4.5 | |||||||
4.5 | Warrant to purchase stock issued to Hercules Capital, dated September 17, 2021 | 10-Q | 11-8-2021 | 10.2 | |||||||
4.6 | Form of Warrant to purchase stock issuable pursuant to the Loan and Security Agreement, as amended, by and between the Registrant and Hercules Capital, Inc. | 10-Q | 5-10-2023 | 4.6 | |||||||
4.7 | First Amendment to Warrant to purchase stock issued to Hercules Capital, dated May 9, 2023 | 10-Q | 5-10-2023 | 4.5 | |||||||
4.8 | Description of Registered Securities | X | |||||||||
10.1# | Phathom Pharmaceuticals, Inc. 2019 Equity Incentive Plan | S-1 | 9-30-2019 | 10.1 | |||||||
10.2# | Form of Stock Option Grant Notice and Stock Option Agreement under the Phathom Pharmaceuticals, Inc. 2019 Equity Incentive Plan | S-1 | 9-30-2019 | 10.2 | |||||||
10.3# | Form of Restricted Stock Grant Notice and Restricted Stock Agreement under Phathom Pharmaceuticals, Inc. 2019 Equity Incentive Plan | S-1 | 9-30-2019 | 10.3 | |||||||
10.4# | Phathom Pharmaceuticals, Inc. 2019 Incentive Award Plan | S-1/A | 10-15-2019 | 10.4 | |||||||
10.5# | Form of Stock Option Grant Notice and Stock Option Agreement under the Phathom Pharmaceuticals, Inc. 2019 Incentive Award Plan | 10-Q | 8-6-2020 | 10.3 | |||||||
10.6# | Phathom Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan | S-1/A | 10-15-2019 | 10.5 | |||||||
10.7# | Amended and Restated Non-Employee Director Compensation Policy | 10-Q | 8-10-2023 | 10.2 |
10-K/A
2023 FY
PHAT
Phathom Pharmaceuticals Inc
14 Jun 24
Annual report (amended)
4:05pm
Liability balance as of January 1, 2022 | $ | - | ||
Proceeds from the Revenue Interest Financing Agreement | 100,000 | |||
Less: transaction costs | (4,554) | |||
Less: royalty payments and payables | — | |||
Plus: interest expense | 14,079 | |||
Ending liability balance as of December 31, 2022 | $ | 109,525 | ||
Liability balance as of January 1, 2023 | $ | 109,525 | ||
Proceeds from the Revenue Interest Financing Agreement | 175,000 | |||
Less: transaction costs | (2,325) | |||
Less: royalty payments and payables | — | |||
Plus: interest expense | 24,727 | |||
Ending liability balance as of December 31, 2023 | 306,927 | |||
Less: current portion | (7,111) | |||
Long-term liability balance as of December 31, 2023 | $ | 299,816 |
10-K/A
2023 FY
PHAT
Phathom Pharmaceuticals Inc
14 Jun 24
Annual report (amended)
4:05pm
Number of Stock Units | Weighted- Average Grant Date Fair Value Per Share | |||||||
Unvested balance at January 1, 2022 | — | $ | — | |||||
Granted | 1,010,437 | 10.79 | ||||||
Vested | (102,453) | 8.51 | ||||||
Forfeited | (30,517) | 12.14 | ||||||
Unvested balance at December 31, 2022 | 877,467 | $ | 11.03 | |||||
Granted(1) | 2,419,776 | 11.77 | ||||||
Vested | (579,567) | 9.85 | ||||||
Forfeited | (63,784) | 13.07 | ||||||
Unvested balance at December 31, 2023 | 2,653,892 | $ | 11.91 |
10-K/A
2023 FY
PHAT
Phathom Pharmaceuticals Inc
14 Jun 24
Annual report (amended)
4:05pm
Years Ended December 31, | ||||||||
2023 | 2022 | |||||||
Assumptions: | ||||||||
Expected term (in years) | 0.49 | 0.50 | ||||||
Expected volatility | 69.73 | % | 68.59 | % | ||||
Risk free interest rate | 5.03 | % | 2.04 | % | ||||
Dividend yield | — | — |
10-K/A
m1oxgefw fwjx0a
14 Jun 24
Annual report (amended)
4:05pm
10-K/A
u0frebfr8u3v
14 Jun 24
Annual report (amended)
4:05pm
10-K/A
4oyws37iu2upgf
14 Jun 24
Annual report (amended)
4:05pm
10-K/A
7rf3m9 gr
14 Jun 24
Annual report (amended)
4:05pm
10-K/A
t5cn7wan2zzmibny
14 Jun 24
Annual report (amended)
4:05pm
10-K/A
l0ifo
14 Jun 24
Annual report (amended)
4:05pm
10-K/A
9pq3g
14 Jun 24
Annual report (amended)
4:05pm
10-K/A
wvxrxj 781qq0ttxga
14 Jun 24
Annual report (amended)
4:05pm
10-K/A
gwbk4awxs34ckrko3f0
14 Jun 24
Annual report (amended)
4:05pm
10-K/A
sqbbm4znxkq07g4u1hq
14 Jun 24
Annual report (amended)
4:05pm
10-K/A
4armbz4l2i6nx
14 Jun 24
Annual report (amended)
4:05pm
10-K/A
pwi4728a
14 Jun 24
Annual report (amended)
4:05pm
10-K/A
adpujr nf0h8p
14 Jun 24
Annual report (amended)
4:05pm
10-K/A
b4p44hfa4vxq oxn
14 Jun 24
Annual report (amended)
4:05pm
10-K/A
m5rqwn2h7xrsr
14 Jun 24
Annual report (amended)
4:05pm